Eucalyptus’ US buyer Hims & Hers is in a world of pain right now
The Australian weight-loss unicorn is being eaten up by a US company battling ongoing legal drama, a surge in short sellers, and a spiralling share price.
When the dust settles on Hims & Hers’ $1.6 billion acquisition of Sydney-based Eucalyptus, more than 400 local and global employees will become part of a New York-listed telehealth giant that is currently enduring a bruising stretch on Wall Street.
Shares in San Francisco-headquartered Hims & Hers have more than halved since the start of 2026 as it grapples with legal issues, competition pressure and revenue concerns.
The stock was pushed even lower on Tuesday after the company reported its fourth-quarter earnings.
Some USD910 million, or $1.3 billion of the Eucalyptus sale price comprises deferred payments that could be paid in Hims & Hers equity, under the terms of the deal.
